No connection

Search Results

INMD vs TBPH

INMD
InMode Ltd.
NEUTRAL
Price
$13.53
Market Cap
$857.2M
Sector
Healthcare
AI Confidence
85%
TBPH
Theravance Biopharma, Inc.
NEUTRAL
Price
$16.72
Market Cap
$861.0M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
INMD
9.46
TBPH
8.12
Forward P/E
INMD
8.84
TBPH
12.34
P/B Ratio
INMD
1.25
TBPH
2.88
P/S Ratio
INMD
2.31
TBPH
8.01
EV/EBITDA
INMD
3.6
TBPH
-297.73

Profitability

Gross Margin
INMD
78.53%
TBPH
65.19%
Operating Margin
INMD
25.03%
TBPH
43.6%
Profit Margin
INMD
25.33%
TBPH
98.54%
ROE
INMD
13.53%
TBPH
44.84%
ROA
INMD
6.88%
TBPH
-0.54%

Growth

Revenue Growth
INMD
6.1%
TBPH
144.7%
Earnings Growth
INMD
-63.5%
TBPH
--

Financial Health

Debt/Equity
INMD
0.01
TBPH
0.14
Current Ratio
INMD
9.88
TBPH
10.93
Quick Ratio
INMD
8.55
TBPH
10.73

Dividends

Dividend Yield
INMD
--
TBPH
--
Payout Ratio
INMD
0.0%
TBPH
0.0%

AI Verdict

INMD NEUTRAL

InMode presents a classic 'value trap' profile, characterized by a weak Piotroski F-Score of 3/9 and a completely bearish technical trend (0/100). While the company maintains an exceptional balance sheet with virtually no debt (Debt/Equity 0.01) and extreme liquidity (Current Ratio 9.88), these strengths are offset by a severe collapse in earnings growth (-63.50% YoY). The stock trades below its Graham Number ($18.63) but above its growth-based intrinsic value ($10.01), suggesting that while it is cheap on a book-value basis, its growth trajectory is deteriorating.

Strengths
Exceptional gross margins of 78.53%
Virtually debt-free balance sheet (Debt/Equity 0.01)
Extreme short-term liquidity with a Current Ratio of 9.88
Risks
Severe earnings contraction (-63.50% YoY)
Strongly bearish technical momentum (0/100 trend score)
Deteriorating fundamental health as indicated by Piotroski F-Score (3/9)
TBPH NEUTRAL

TBPH presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation trading very close to its Graham Number ($16.41) and Intrinsic Value ($14.42). While the company exhibits explosive revenue growth (144.7% YoY) and an exceptionally strong liquidity position (Current Ratio 10.93), these fundamentals are countered by bearish insider sentiment and a negative technical trend. The current price of $16.72 suggests the stock is fully valued based on deterministic models, leaving little margin of safety despite the low P/E ratio.

Strengths
Explosive YoY revenue growth of 144.70%
Exceptional liquidity with a Current Ratio of 10.93
Very low leverage with a Debt/Equity ratio of 0.14
Risks
Strongly bearish insider activity with 5 sell transactions and 0 buys
Bearish technical trend (0/100 score)
Highly volatile quarterly earnings track record with frequent misses

Compare Another Pair

INMD vs TBPH: Head-to-Head Comparison

This page compares InMode Ltd. (INMD) and Theravance Biopharma, Inc. (TBPH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile